Recombinant human Calcineurin B subunit

重组人钙调蛋白磷酸酶B

Report date: 2025/04/07 15:07:30

Base Information

Drug NameRecombinant human Calcineurin B subunit
Drug Alias Name重组人钙调蛋白磷酸酶B亚基rhCNB
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionCalmodulin modulators
TargetsCalmodulin
Therapy Area/IndicationsMyelodysplastic SyndromesLiver NeoplasmsStomach Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryRussian FederationMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHaikou Qili Pharmaceutical Holdings Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesFederal Research Institute of Pediatric Hematology Oncology and ImmunologyBeijing Normal UniversityHaikou Qili Pharmaceutical Holdings Co Ltd
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesLiver NeoplasmsStomach Neoplasms +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A